Review
Programmable elution profile coating for drug eluting stents
Affiliations
- PMID: 15828493
Item in Clipboard
Review
Programmable elution profile coating for drug eluting stents
Med Device Technol.
2005 Mar.
Abstract
Despite good results in reducing in-stent restenosis during cardiac stenting procedures, a number of issues in the application of drug-eluting stents still challenge the industry. These include drug-elution kinetics and long-term biocompatibility. Some of the latest developments in these areas are described here.
Similar articles
-
Local perivascular delivery of anti-restenotic agents from a drug-eluting poly(epsilon-caprolactone) stent cuff.Biomaterials. 2005 Sep;26(26):5386-94. doi: 10.1016/j.biomaterials.2005.01.063. Biomaterials. 2005. PMID: 15814137
-
Drug-eluting stents, restenosis and revascularization.Herz. 2007 Jun;32(4):287-95. doi: 10.1007/s00059-007-2994-z. Herz. 2007. PMID: 17607535 Review.
-
Drug loading and elution from a phosphorylcholine polymer-coated coronary stent does not affect long-term stability of the coating in vivo.Biomed Mater Eng. 2004;14(4):355-70. Biomed Mater Eng. 2004. PMID: 15472385
-
Coronary restenotic reduction of drug-eluting stenting may be due to its anti-inflammatory effects.Med Hypotheses. 2007;69(5):1004-9. doi: 10.1016/j.mehy.2007.01.090. Epub 2007 May 11. Med Hypotheses. 2007. PMID: 17499449
-
Coronary stents: a materials perspective.Biomaterials. 2007 Mar;28(9):1689-710. doi: 10.1016/j.biomaterials.2006.11.042. Epub 2006 Dec 22. Biomaterials. 2007. PMID: 17188349 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources